VRTX - Vertex Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Profile Performance Price Targets & Ratings Chart Insider Trading

VRTX is currently covered by 28 analysts with an average price target of $431.03. This is a potential upside of $36.86 (9.35%) from yesterday's end of day stock price of $394.17.

Vertex Pharmaceuticals's activity chart (see below) currently has 403 price targets and 390 ratings on display. The stock rating distribution of VRTX is 2.63% SELL, 64.04% BUY and 33.33% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 90.79% with an average time for these price targets to be met of 226.83 days.

Highest price target for VRTX is $559, Lowest price target is $328, average price target is $431.03.

Most recent stock forecast was given by BRIAN ABRAHAMS from RBC on 06-Feb-2024. First documented stock forecast 29-May-2012.

Split History since 2000:

8/24/00 2 for 1

What is Vertex Pharmaceuticals?

Vertex Pharmaceuticals is a biotechnology company that develops and commercializes therapies for treating cystic fibrosis (CF), a genetic disease that affects the lungs and digestive system. Vertex founded in 1989 at Boston, Massachusetts.

Products of Vertex Pharmaceuticals

TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI

Regulators have approved these medications for the treatment of patients aged 6 years or older with at least one F508del mutation.

ORKAMBI

The FDA has approved this medication for treating CF homozygous F508del mutation patients aged 2 years or older.

KALYDECO

Which was approved by the U.S. Food and Drug Administration (FDA) in 2012. KALYDECO is a medication that is approved for treating CF patients who have a specific mutation that is responsive to ivacaftor.

In addition to these drugs, Vertex Pharmaceuticals has a pipeline of drugs in various stages of clinical development. VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, is currently in Phase 1 clinical trials. VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain, is in Phase 3 clinical trials. The company is also developing Exa-cel for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia, which is in Phase 2/3 clinical trials, and VX-864 for the treatment of alpha-1 antitrypsin (AAT) deficiency, which is in Phase 2 clinical trials. The company is also developing drugs to treat cancer and other genetic diseases.

Vertex Pharmaceuticals’ Performance History

The company had also entered into collaborations with several biotechnology firms, such as CRISPR Therapeutics, Moderna, Entrada Therapeutics, Affinia Therapeutics, Arbor Biotechnologies, Kymera Therapeutics, Mammoth Biosciences, Obsidian Therapeutics, Verve Therapeutics, Skyhawk Therapeutics, and Ribometrix.

Vertex Pharmaceuticals’ contribution to treating CF has been recognized through its products. The FDA approved TRIKAFTA/KAFTRIO in 2018, and it was later approved in Europe in 2019.

The drug demonstrated significant improvement in lung function and quality of life in CF patients.

Currently out of the existing stock ratings of VRTX, 3 are a SELL (2.63%), 73 are a BUY (64.04%), 38 are a HOLD (33.33%).

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

420

$15.78 (3.90%)

397

2 months 12 days ago

27/33 (81.82%)

$3.87 (0.93%)

187

Buy

450

$45.78 (11.33%)

438

2 months 12 days ago

2/4 (50%)

$33.87 (8.14%)

89

Buy

457

$52.78 (13.06%)

397

2 months 12 days ago

15/16 (93.75%)

$40.87 (9.82%)

210

Buy

540

$135.78 (33.59%)

500

2 months 12 days ago

13/15 (86.67%)

$123.87 (29.77%)

331

Hold

438

$33.78 (8.36%)

436

2 months 12 days ago

5/6 (83.33%)

$21.87 (5.26%)

104

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is VRTX (Vertex Pharmaceuticals) average time for price targets to be met?

On average it took 226.83 days on average for the stock forecasts to be realized with a an average price target met ratio 90.79

Which analyst has the current highest performing score on VRTX (Vertex Pharmaceuticals) with a proven track record?

SALVEEN RICHTER

Which analyst has the most public recommendations on VRTX (Vertex Pharmaceuticals)?

Salveen Richter works at GOLDMAN SACHS and has 8 price targets and 5 ratings on VRTX

Which analyst is the currently most bullish on VRTX (Vertex Pharmaceuticals)?

Salveen Richter with highest potential upside - $154.78

Which analyst is the currently most reserved on VRTX (Vertex Pharmaceuticals)?

Matthew Roden with lowest potential downside - -$244.22

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?